Medical Device News Magazine, in addition to offering a comprehensive view of the latest medical device news and industry information, publishes news on topics such as artificial intelligence (AI), medical manufacturing, other services, and more.
“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”
The launch incorporates learnings from a pilot program with HCA Healthcare (NYSE: HCA), one of the nation's leading healthcare providers. As part of the pilot, ED physicians in four HCA Healthcare hospitals utilized Augmedix Go to automate medical documentation, with the product instantaneously drafting their medical notes from patient visits.
“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”
ViewRay, Inc. will partner with the largest independent distributor in Australasia, who will market, sell, and support ViewRay's MRIdian MRI-guided radiation therapy system.
4/16/19: As part of this new agreement, Vizient reports The Johns Hopkins Health System Corporation will join Vizient’s group purchasing organization with the expectation of a decrease in its current supply costs.
PredictImmune today confirmed that it has entered into a commercial agreement with Addenbrooke’s hospital, part of Cambridge University Hospitals NHS Foundation Trust, to provide PredictSURE IBD™ to clinicians and gastroenterologists in the UK and Ireland.
Under the agreement, the East Midlands and East of England Genomic Laboratory Hub based at Addenbrooke’s Hospital will manage and facilitate the fulfillment of orders of PredictSURE IBD™, as well as receive and process all samples.
This agreement gives UK IBD patients access to the world’s...
By using this website you agree to accept Medical Device News Magazine Privacy Policy
